cancer drug costs

Cancer Drug Spending SoarsNew therapies and increased awareness lead to a large market.
Multiple myeloma treatment advances: What health execs should knowIt has been an exciting time at the Myeloma Institute at the University of Arkansas for Medical Sciences, on all fronts, namely, embarking on research that could play an important role in the development of preventative and curative strategies for multiple myeloma in the future.
Four things health execs should know about the oncology pipeline
Four things health execs should know about the oncology pipelineHere’s how you can recognize changes in the oncology pipeline and maximize value related to cancer care.
Sharp price increases for cancer drugs
Sharp price increases for cancer drugsA majority of oncology drugs—particularly older cancer drugs—had price hikes in 2015, according to a study. Plus, Ariad Pharmaceuticals raised the price of its chronic myeloid leukemia (CML) drug ponatinib (Iclusig) for the fourth time this year to around $199,000 a year, according to The Street.
Are oncology pathways effective? AMCP presenters weigh inFaced with a proliferation of oncology treatments, payers have started using oncology pathways. But what do these programs look like, and are they really working?
Oversized cancer drug vials lead to billions in waste annuallyAs healthcare expenditures rise, researchers from Memorial Sloan Kettering Cancer Center propose ways to reduce waste and cut costs.
CVS, Express Scripts plan value-based drug pricingThe approaches reflect a growing number of initiatives meant to tie drug prices to value. Find out more.